<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02202928</url>
  </required_header>
  <id_info>
    <org_study_id>HYK-Colorectal Cancer</org_study_id>
    <nct_id>NCT02202928</nct_id>
  </id_info>
  <brief_title>Adoptive Cell Therapy Plus Chemotherapy and Radiation After Surgery in Treating Patients With Colorectal Cancer</brief_title>
  <official_title>Phase 2 Study of Autologous Tumor Lysate-pulsed DC-CIK Cell in Colorectal Cancer After Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen Hornetcorn Bio-technology Company, LTD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jingzhou Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shenzhen Hornetcorn Bio-technology Company, LTD</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of autologous tumor lysate-pulsed
      dendritic and cytokine-induced killer cells (DC-CIK) for colorectal cancer (CRC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      60 patients with stageⅠ~ Ⅲ CRC, who had received surgery and kept their tumor tissue, will be
      randomly divided into group A (receive DC-CIK treatment, chemotherapy and radiotherapy) or
      group B (just receive chemotherapy and radiotherapy), and the randomize ratio will be 1:1.
      Patients in group A will receive 3 cycles of autologous tumor lysate pulsed DC-CIK cells
      treatment (every 4 weeks) and 4 cycles chemo-radiotherapy. Patients in group B will receive
      only 4 cycles chemo-radiotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progress-free survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QOL)</measure>
    <time_frame>3 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phenotypic analysis of T cells</measure>
    <time_frame>1 year</time_frame>
    <description>The number of CD3+ (or CD8+ or CD4+ or CD56+) T cell</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Neoplasms</condition>
  <condition>Intestinal Neoplasms</condition>
  <condition>Digestive System Neoplasms</condition>
  <condition>Gastrointestinal Diseases</condition>
  <arm_group>
    <arm_group_label>Chemo-radiotherapy</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>After accepting concurrent radiotherapy and chemotherapy according to NCCN guidelines, patients will just regularly follow up.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DC-CIK</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After accepting concurrent radiotherapy and chemotherapy according to NCCN guidelines, patients will receive 3 cycles of autologous tumor lysate pulsed DC-CIK treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DC-CIK</intervention_name>
    <description>8×10^9 autologous tumor lysate pulsed DC-CIK cells for each infusion, IV (in the vein) for four cycles, each cycle received four infusions with a 1 day interval.</description>
    <arm_group_label>DC-CIK</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>45~50 Gy in 25-28 fractions.</description>
    <arm_group_label>Chemo-radiotherapy</arm_group_label>
    <arm_group_label>DC-CIK</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Oxaliplatin 85mg/m2 IV over 2 hours, day 1; Leucovorin 400mg/m2 IV over 2 hours, day 1; 5-FU 400mg/m2 IV bolus on day 1, then 1200mg/m2/day for 2 days IV continuous infusion; Repeat every 2 weeks.</description>
    <arm_group_label>Chemo-radiotherapy</arm_group_label>
    <arm_group_label>DC-CIK</arm_group_label>
    <other_name>FOLFOX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18~80 years old;

          -  Histologically confirmed with colorectal cancer at stage Ⅰ~Ⅲ;

          -  Patients who can accept curative operations;

          -  Patients who have a life expectancy of at least 3 months;

          -  Eastern Cooperative Oncology Group (ECOG) performance status was 0 - 1.

        Exclusion Criteria:

          -  Hemoglobin＜8.0 g/dL,Platelet count ＜75 x 10^9/L; ALT, AST, BUN and Cr more than normal
             limits on 3.0 times ;

          -  Known or suspected allergy to the investigational agent or any agent given in
             association with this trial;

          -  Pregnant or lactating patients;

          -  Known history of Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV) or
             TreponemaPallidun (TP) infection;

          -  Patients who are suffering from serious autoimmune disease;

          -  History of organ allograft;

          -  Patients who had distant metastases;

          -  Patients who had active infection;

          -  Prior use of any anti-cancer treatment in 30 days;

          -  Now or recently will join another experimental clinical study ;

          -  Other situations that the researchers considered unsuitable for this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ke N Zhang, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jingzhou Central Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jingzhou Central Hospital Immunotherapy center</name>
      <address>
        <city>Jingzhou</city>
        <state>Hubei</state>
        <zip>434020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2014</study_first_submitted>
  <study_first_submitted_qc>July 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2014</study_first_posted>
  <last_update_submitted>December 23, 2015</last_update_submitted>
  <last_update_submitted_qc>December 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal cancer</keyword>
  <keyword>DC-CIK</keyword>
  <keyword>Autologous tumor lysate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
    <mesh_term>Digestive System Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

